Journal - Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Topic(s) Covered

1 Topic(s)

View

Aims & Scope

This journal is devoted to timely reviews of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Topics related to the neuroendocrine-immune axis are given special emphasis in view of the growing interest in stress-related, inflammatory, autoimmune, and degenerative disorders. Original articles related to Immune Disorders and Drug Targeting are also considered for publication.

Abstracted/Indexed in

Dimensions, Science Citation Index (Thomson Reuters), BIOSIS Previews, BIOSIS Reviews Reports and Meetings, MEDLINE/PubMed/Index Medicus, Scopus, EMBASE/Excerpta Medica, Chemical Abstracts, ProQuest, Genamics JournalSeek, MediaFinder®-Standard Periodical Directory, PubsHub and J-Gate.

Special Offers

New eBook

Immune Response to Parasitic Infections: Immunity to Helminths and Novel Therapeutic Approaches
You can view the contents of this
eBook [here] .

Endorsement(s)

"EMID-DT is a prestigious journal with a multidisciplinary coverage. Its aim is to provide cutting- edge information to readers working in different field of research ranging from immune endocrine to metabolic disorders."

Chris Galanos
Max Planck Institude, Germany

Authors' Comments

To be in a rush to publish and to produce a high quality product are the two most important things that Bentham science has efficiently accomplished for me. The review process went smooth and easy. The post publishing services are remarkable. In total, it was an interesting experience.

Dr. Kyrillus S. Shohdy
(Cairo University Hospitals, Al-Saray St., El-Maniel, 11451, Cairo, Egypt)

Has contributed: GPR 120: The Potential Target for Obesity Treatment